Aug 30, 2021
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Aug 26, 2021
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Aug 04, 2021
Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003
Jul 13, 2021
Immutep Quarterly Activities Report
Jul 05, 2021
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
